11.29
Wave Life Sciences Ltd stock is traded at $11.29, with a volume of 165.36K.
It is down -4.42% in the last 24 hours and down -13.48% over the past month.
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
See More
Previous Close:
$11.84
Open:
$12.09
24h Volume:
165.36K
Relative Volume:
0.17
Market Cap:
$1.81B
Revenue:
$53.61M
Net Income/Loss:
$-142.52M
P/E Ratio:
-10.17
EPS:
-1.11
Net Cash Flow:
$-141.83M
1W Performance:
-2.18%
1M Performance:
-13.48%
6M Performance:
+89.25%
1Y Performance:
+182.22%
Wave Life Sciences Ltd Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd
Sector
Industry
Phone
617-949-2900
Address
7 STRAITS VIEW, SINGAPORE
Compare WVE with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
WVE
Wave Life Sciences Ltd
|
11.29 | 1.81B | 53.61M | -142.52M | -141.83M | -1.11 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.22 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
651.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
274.97 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
118.68 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-16-24 | Upgrade | Raymond James | Outperform → Strong Buy |
Sep-27-24 | Resumed | JP Morgan | Overweight |
Sep-19-24 | Initiated | B. Riley Securities | Buy |
Sep-09-24 | Initiated | JP Morgan | Overweight |
May-15-24 | Initiated | Wells Fargo | Overweight |
Dec-19-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
Jul-05-23 | Initiated | Raymond James | Outperform |
May-24-23 | Downgrade | Jefferies | Buy → Hold |
Dec-15-20 | Resumed | H.C. Wainwright | Buy |
Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Nov-01-19 | Initiated | Guggenheim | Buy |
Jul-15-19 | Initiated | Cowen | Market Perform |
Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
Aug-07-18 | Initiated | Stifel | Buy |
Jul-23-18 | Initiated | H.C. Wainwright | Buy |
Mar-19-18 | Reiterated | Mizuho | Buy |
Feb-15-17 | Initiated | H.C. Wainwright | Buy |
Nov-10-16 | Resumed | Leerink Partners | Outperform |
Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
Dec-07-15 | Initiated | Jefferies | Buy |
Dec-07-15 | Initiated | Leerink Partners | Outperform |
Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd Stock (WVE) Latest News
Wave Life Sciences begins Phase 1 obesity trial By Investing.com - Investing.com Nigeria
Wave Life Sciences begins Phase 1 obesity trial - MSN
Wave Life Sciences Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity - GlobeNewswire
Revolutionary Once-Yearly Obesity Drug Enters Human Trials: Wave's WVE-007 Takes On Wegovy - StockTitan
Wave Life Sciences Ltd. (NASDAQ:WVE) Receives $22.22 Average PT from Analysts - MarketBeat
Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Recommendation of “Buy” by Brokerages - Defense World
BlackRock, Inc. Expands Stake in WAVE Life Sciences Ltd - GuruFocus.com
Wave Life Sciences Ltd (WVE) requires closer examination - US Post News
Wave Life Sciences (NASDAQ:WVE) Stock Price Down 3.6%What's Next? - MarketBeat
Is Wave Life Sciences Ltd (WVE) positioned for future growth? - SETE News
Wave Life Sciences (NASDAQ:WVE) shareholders have earned a 69% CAGR over the last three years - Yahoo Finance
Raymond James gives a Strong buy recommendation for Wave Life Sciences Ltd (WVE) - Knox Daily
China Universal Asset Management Co. Ltd. Boosts Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by Moody Aldrich Partners LLC - MarketBeat
SG Americas Securities LLC Boosts Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Where are the Opportunities in (WVE) - Stock Traders Daily
Wave Life Sciences (NASDAQ:WVE) delivers shareholders enviable 72% CAGR over 3 years, surging 8.5% in the last week alone - Simply Wall St
(WVE) Trading Advice - Stock Traders Daily
JPMorgan Chase & Co. Sells 16,382 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences Updates Corporate Presentation in 8-K Filing - Defense World
Wave Wants To Put The Joy Back Into Weight-Loss Drugs - Citeline
Is Wave Life Sciences (WVE) the Top Small Cap Stock to Buy with the Highest Upside Potential? - Yahoo Finance
Wave Life Sciences Highlights Strategic Priorities and Expected 2025 Milestones Ahead of J.P. Morgan Presentation - GlobeNewswire
Wave Life Sciences Advances Obesity Drug WVE-007, Reports Strong DMD Treatment Results - StockTitan
Barclays PLC Has $1.31 Million Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Top 10 Small Cap Stocks to Buy with the Highest Upside Potential - Insider Monkey
WAVE Life Sciences (FRA:1U5) Cash From Discontinued Investi - GuruFocus.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Given Average Recommendation of “Buy” by Analysts - Defense World
Wave Life Sciences Ltd. (NASDAQ:WVE) Receives $22.22 Average Target Price from Brokerages - MarketBeat
12 Best Growth Stocks Under $25 to Buy Now - Insider Monkey
Is Wave Life Sciences Ltd. (WVE) the Best Growth Stock to Buy Now Under $25? - Yahoo Finance
How to Take Advantage of moves in (WVE) - Stock Traders Daily
Wave Life Sciences Is A Buy On Pipeline Prospects (WVE) - Seeking Alpha
Wave Life Sciences (NASDAQ:WVE) Trading Down 4%Here's What Happened - MarketBeat
Wave Life Sciences (NASDAQ:WVE) Stock Price Up 7.7%What's Next? - MarketBeat
Franklin Resources Inc. Cuts Stock Position in Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Learn to Evaluate (WVE) using the Charts - Stock Traders Daily
Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Purchased by Barclays PLC - MarketBeat
Geode Capital Management LLC Increases Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Barclays PLC Acquires 100,498 Shares of Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
Wave Life Sciences (NASDAQ:WVE) Stock Price Down 2.6%Here's Why - MarketBeat
Wave files clinical trial application for WVE-007 - BioWorld Online
State Street Corp Has $19.03 Million Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE) - MarketBeat
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity - The Manila Times
Wave Life Sciences Announces Submission of First Clinical - GlobeNewswire
Wave Life Sciences Advances Novel Obesity Drug WVE-007 Targeting INHBE Gene; Clinical Trials Set for 2025 - StockTitan
XTX Topco Ltd Buys Shares of 15,334 Wave Life Sciences Ltd. (NASDAQ:WVE) - Defense World
WAVE Life Sciences (FRA:1U5) Other Long-Term Liabilities : €7.09 Mil (As of Sep. 2024) - GuruFocus.com
WAVE Life Sciences (FRA:1U5) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
(WVE) Investment Analysis - Stock Traders Daily
Wave Life Sciences Ltd Stock (WVE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Wave Life Sciences Ltd Stock (WVE) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
BOLNO PAUL | President and CEO |
Nov 25 '24 |
Option Exercise |
2.48 |
50,000 |
124,000 |
267,351 |
BOLNO PAUL | President and CEO |
Nov 25 '24 |
Sale |
15.00 |
50,000 |
750,000 |
217,351 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):